MX377725B - Combinación que comprende un compuesto de aminotioléster o una de sus sales farmacéuticamente aceptables y un compuesto capaz de aumentar el nivel de peróxido de hidrógeno (h2o2) en las células cancerosas de un sujeto. - Google Patents
Combinación que comprende un compuesto de aminotioléster o una de sus sales farmacéuticamente aceptables y un compuesto capaz de aumentar el nivel de peróxido de hidrógeno (h2o2) en las células cancerosas de un sujeto.Info
- Publication number
- MX377725B MX377725B MX2018004381A MX2018004381A MX377725B MX 377725 B MX377725 B MX 377725B MX 2018004381 A MX2018004381 A MX 2018004381A MX 2018004381 A MX2018004381 A MX 2018004381A MX 377725 B MX377725 B MX 377725B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- compound
- subject
- pharmaceutically acceptable
- level
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/36—Arsenic; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Una combinación que comprende un compuesto de aminotioléster o una sal farmacéuticamente aceptable del mismo y un compuesto capaz de aumentar el nivel de H2O2 en las células cancerosas de un sujeto, para usarse como un medicamento. La presente invención se refiere a una combinación que comprende un compuesto de aminotioléster o una sal farmacéuticamente aceptable del mismo, en particular el 4-(dimetilamino)-4-metilpent-2-inotioato de S-metilo o una sal farmacéuticamente aceptable del mismo, y más particularmente el fumarato del éster S-metílico del ácido 4-(dimetilamino)-4-metil-2-pentinotioico, y un compuesto capaz de aumentar el nivel de H2O2 en las células cancerosas de un sujeto, en particular para usarse en el tratamiento del cáncer en un sujeto, en donde las células cancerosas del sujeto no producen en exceso H2O2 en comparación con un valor de control y tiene un nivel de GSH por debajo de 5 nmol para 25000 células.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306650 | 2015-10-15 | ||
| PCT/EP2016/074682 WO2017064241A1 (en) | 2015-10-15 | 2016-10-14 | Combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof and a compound able to increase the h2o2 level in cancer cells of a subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018004381A MX2018004381A (es) | 2018-05-11 |
| MX377725B true MX377725B (es) | 2025-03-11 |
Family
ID=54360386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018004381A MX377725B (es) | 2015-10-15 | 2016-10-14 | Combinación que comprende un compuesto de aminotioléster o una de sus sales farmacéuticamente aceptables y un compuesto capaz de aumentar el nivel de peróxido de hidrógeno (h2o2) en las células cancerosas de un sujeto. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10406125B2 (es) |
| EP (1) | EP3362094B1 (es) |
| JP (1) | JP7062592B2 (es) |
| CN (1) | CN108348612A (es) |
| AR (1) | AR106351A1 (es) |
| CA (1) | CA3001201C (es) |
| CY (1) | CY1123916T1 (es) |
| DK (1) | DK3362094T3 (es) |
| ES (1) | ES2870508T3 (es) |
| HR (1) | HRP20210358T1 (es) |
| HU (1) | HUE054247T2 (es) |
| IL (1) | IL258658B (es) |
| LT (1) | LT3362094T (es) |
| MX (1) | MX377725B (es) |
| PL (1) | PL3362094T3 (es) |
| PT (1) | PT3362094T (es) |
| RS (1) | RS61572B1 (es) |
| SI (1) | SI3362094T1 (es) |
| SM (1) | SMT202100270T1 (es) |
| WO (1) | WO2017064241A1 (es) |
| ZA (1) | ZA201802400B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA57224B1 (fr) * | 2019-07-31 | 2022-10-31 | Advanced Biodesign | Aminothiolesters et leurs utilisations |
| FR3119314B1 (fr) * | 2021-01-29 | 2025-01-10 | Advanced Biodesign | Nanocapsule lipidique comprenant au moins un composé aminothiolester ou un de ses dérivés pharmaceutiquement acceptable |
| EP4035666A1 (en) * | 2021-01-29 | 2022-08-03 | Advanced Biodesign | Aminothiolester compound or derivative thereof for use as an immunomodulatory agent |
| WO2025229179A1 (en) * | 2024-05-03 | 2025-11-06 | Advanced Biodesign | Use of aminothiolester compounds in combination with hypomethylating agents (hma) for the prevention and treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2777001B1 (fr) * | 1998-04-01 | 2000-06-09 | Cird Galderma | Derives de l'acide 6,8-dimercaptooctanoique substitues en 6-s et/ou en 8-s par le radical (3-methylthiopropanoyl) et compositions pharmaceutiques destinees au traitement des tumeurs cancereuses |
| FR2809727B1 (fr) | 2000-05-31 | 2002-07-26 | Galderma Res & Dev | Nouveaux composes aminothiolesters, compositions pharmaceutiques et cosmetiques les contenant et utilisations |
-
2016
- 2016-10-14 EP EP16784442.2A patent/EP3362094B1/en active Active
- 2016-10-14 ES ES16784442T patent/ES2870508T3/es active Active
- 2016-10-14 HR HRP20210358TT patent/HRP20210358T1/hr unknown
- 2016-10-14 AR ARP160103143A patent/AR106351A1/es unknown
- 2016-10-14 SI SI201631109T patent/SI3362094T1/sl unknown
- 2016-10-14 US US15/768,468 patent/US10406125B2/en active Active
- 2016-10-14 PL PL16784442T patent/PL3362094T3/pl unknown
- 2016-10-14 JP JP2018538936A patent/JP7062592B2/ja active Active
- 2016-10-14 LT LTEP16784442.2T patent/LT3362094T/lt unknown
- 2016-10-14 WO PCT/EP2016/074682 patent/WO2017064241A1/en not_active Ceased
- 2016-10-14 DK DK16784442.2T patent/DK3362094T3/da active
- 2016-10-14 CN CN201680066560.4A patent/CN108348612A/zh active Pending
- 2016-10-14 MX MX2018004381A patent/MX377725B/es active IP Right Grant
- 2016-10-14 HU HUE16784442A patent/HUE054247T2/hu unknown
- 2016-10-14 SM SM20210270T patent/SMT202100270T1/it unknown
- 2016-10-14 RS RS20210309A patent/RS61572B1/sr unknown
- 2016-10-14 PT PT167844422T patent/PT3362094T/pt unknown
- 2016-10-14 CA CA3001201A patent/CA3001201C/en active Active
-
2018
- 2018-04-12 IL IL258658A patent/IL258658B/en active IP Right Grant
- 2018-04-12 ZA ZA2018/02400A patent/ZA201802400B/en unknown
-
2021
- 2021-03-02 CY CY20211100174T patent/CY1123916T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3362094A1 (en) | 2018-08-22 |
| US20180303773A1 (en) | 2018-10-25 |
| WO2017064241A1 (en) | 2017-04-20 |
| RS61572B1 (sr) | 2021-04-29 |
| AR106351A1 (es) | 2018-01-03 |
| MX2018004381A (es) | 2018-05-11 |
| HUE054247T2 (hu) | 2021-08-30 |
| SI3362094T1 (sl) | 2021-04-30 |
| BR112018007480A2 (en) | 2018-10-23 |
| DK3362094T3 (da) | 2021-03-01 |
| CY1123916T1 (el) | 2022-05-27 |
| ES2870508T3 (es) | 2021-10-27 |
| IL258658A (en) | 2018-06-28 |
| SMT202100270T1 (it) | 2021-07-12 |
| JP2018531995A (ja) | 2018-11-01 |
| ZA201802400B (en) | 2020-01-29 |
| CA3001201A1 (en) | 2017-04-20 |
| HK1251477A1 (en) | 2019-02-01 |
| HRP20210358T1 (hr) | 2021-04-16 |
| JP7062592B2 (ja) | 2022-05-06 |
| CN108348612A (zh) | 2018-07-31 |
| CA3001201C (en) | 2023-07-11 |
| LT3362094T (lt) | 2021-05-10 |
| IL258658B (en) | 2021-04-29 |
| PT3362094T (pt) | 2021-04-15 |
| US10406125B2 (en) | 2019-09-10 |
| EP3362094B1 (en) | 2021-02-17 |
| PL3362094T3 (pl) | 2021-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021008281A (es) | Estimuladores de guanilato ciclasa soluble (sgc). | |
| MX389597B (es) | Inhibidores de cdk2/4/6 de piridopirimidinona. | |
| ZA201606320B (en) | Human plasma kallikrein inhibitors | |
| TN2016000529A1 (en) | Substituted dihydroisoquinolinone compounds | |
| NZ734233A (en) | Pharmaceutical compositions comprising meloxicam | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MY192055A (en) | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation | |
| CY1123916T1 (el) | Συνδυασmος που περιλαμβανει mιa ενωση αμινοθειολεστερα ή ενα φαρμακευτικως αποδεκτο αλας αυτης και mιa ενωση ικανη αυξησης του επιπεδου η2ο2 στα καρκινικα κυτταρα ενος υποκειμενου | |
| MX389591B (es) | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA | |
| MX2016011105A (es) | Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos. | |
| MX2015015162A (es) | Agente de reduccion de acido urico. | |
| MX2021010297A (es) | Inhibidores de calicreina plasmatica humana. | |
| TN2017000342A1 (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones | |
| MX381721B (es) | Compuestos de aminotiolesteres o sus sales farmaceuticamente aceptables para usarse en el tratamiento del cancer. | |
| TN2017000448A1 (en) | Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease | |
| EP3881845A3 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
| PH12016502527B1 (en) | Stabilized desmopressin | |
| NZ780408A (en) | Human plasma kallikrein inhibitors | |
| UA92840U (uk) | Дегідратаційно-дегреасингаційний розчин для пластинації анатомічних препаратів |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |